Key result
This review focuses on the use of platelet glycoprotein IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to standard thrombolytic treatment for acute myocardial infarction.
Why the study?
Does the use of GP IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to thrombolytic treatment improve outcomes in patients with acute myocardial infarction?
Does the use of GP IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to thrombolytic treatment improve outcomes in patients with acute myocardial infarction?
This review discusses the potential of GP IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to thrombolysis in acute myocardial infarction.
Adjunctive GP IIb/IIIa antagonists and thrombin inhibitors may improve AMI outcomes with thrombolysis; extends evidence for optimized antithrombotic regimens in reperfusion.
Thrombolysis and percutaneous transluminal angioplasty represent the cornerstone of the pharmacologic treatment of and the interventional approach to patients with myocardial infarction (MI). They are very effective. However, they are hampered by some critical limitations. Therefore, alternatives to standard thrombolytic therapy have been developed. Platelet glycoprotein (GP) IIb/IIIa blockade is under investigation and seems very attractive. This review will focus on the use of GP IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to the thrombolytic treatment of patients with acute MI.
No takes yet. Share an insight, caveat, or question.
Helft et al. (2000) conducted a review in Acute myocardial infarction. Glycoprotein IIb/IIIa antagonists and thrombin inhibitors was evaluated. This review focuses on the use of platelet glycoprotein IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to standard thrombolytic treatment for acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: